Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as
additional conduits for metastatic spread. The identification of growth factor receptor …

Anti-angiogenic therapies target the tumor vasculature, impairing its development and
growth. It was hypothesized over 40 years ago by the late Judah Folkman and Julie …

Approval of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab by the
FDA in 2004 reflected the success of this vascular targeting strategy in extending survival in …

Anti-VEGF pathway therapies primarily target immature blood vessels in tumors. However,
emerging approaches to combine with targeted therapies impacting the later stages of …

Our analyses in several different tumor settings challenge the prevailing view that
malignancies and metastases generally initiate as avascular masses that only belatedly …

Abstract The angiopoietins Ang1 (ANGPT1) and Ang2 (ANGPT2) are secreted factors that
bind to the endothelial cell–specific receptor tyrosine kinase Tie2 (TEK) and regulate …

Abstract Angiopoietins (ANG-1 and ANG-2) and their TIE-2 receptor tyrosine kinase have
wide-ranging effects on tumor malignancy that includes angiogenesis, inflammation, and …

Angiogenesis is the process of formation of new blood vessels from existing ones. Vessels
serve the purpose of providing oxygen, nutrients and removal of waste from the cells. The …

How do angiopoietins Tie in with vascular endothelial growth... : Current Opinion in Hematology
How do angiopoietins Tie in with vascular endothelial growth factors? : Current Opinion in …

Simple Summary The dissemination of cancer cells from their original location to distant
organs where they grow, a process called metastasis, causes more than 90% of cancer …